Comparative analysis between four model nanoformulations of amphotericin B-chitosan, amphotericin B-dendrimer, betulinic acid-chitosan and betulinic acid-dendrimer for treatment of Leishmania major: real-time PCR assay plus

References

• Ponte-Sucre A, Gamarro F, Dujardin J-C, et al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl Trop Dis. 2017;11(12):e0006052. doi:10.1371/journal.pntd.000605229240765
   PubMed Web of Science ®Google Scholar
• Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671. doi:10.1371/journal.pone.003567122693548
   PubMed Web of Science ®Google Scholar
• Galvão EL, Rabello A, Cota GF. Efficacy of azole therapy for tegumentary leishmaniasis: a systematic review and meta-analysis. PLoS One. 2017;12(10):e0186117. doi:10.1371/journal.pone.018611729016694
   PubMedGoogle Scholar
• Ribeiro TG, Franca JR, Fuscaldi LL, et al. An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis. Int J Nanomedicine. 2014;9:5341–5353. doi:10.2147/IJN.S6896625429219
   PubMed Web of Science ®Google Scholar
• Tripathi P, Jaiswal AK, Dube A, Mishra PR. Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of L. donovani. Int J Biol Macromol. 2017;105:625–637. doi:10.1016/j.ijbiomac.2017.07.07628716750
   PubMed Web of Science ®Google Scholar
• Yu B, Okano T, Kataoka K, Kwon G. Polymeric micelles for drug delivery: solubilization and haemolytic activity of amphotericin B. J Controlled Release. 1998;53(1):131–136.
   PubMedGoogle Scholar
• Tripathi P, Dwivedi P, Khatik R, et al. Development of 4-sulfated N-acetyl galactosamine anchored chitosan nanoparticles: a dual strategy for effective management of Leishmaniasis. Colloids Surf B. 2015;136:150–159. doi:10.1016/j.colsurfb.2015.08.037
   PubMed Web of Science ®Google Scholar
• Cole P, Bishop J, Beckstead J, Titus R, Ryan R. Effect of amphotericin B nanodisks on Leishmania major infected mice. Pharm Anal Acta. 2014;5:1–13.
   Google Scholar
• Meira CS, Barbosa-Filho JM, Lanfredi-Rangel A, Guimarães ET, Moreira DRM, Soares MBP. Antiparasitic evaluation of betulinic acid derivatives reveals effective and selective anti-Trypanosoma cruzi inhibitors. Exp Parasitol. 2016;166:108–115. doi:10.1016/j.exppara.2016.04.00727080160
   PubMedGoogle Scholar
• Haavikko R. Synthesis of Betulin Derivatives with New Bioactivities University of Helsinki, Finland: Helsingin yliopisto; 2015:45–49.
   Google Scholar
• Saneja A, Kumar R, Singh A, et al. Development and evaluation of long-circulating nanoparticles loaded with betulinic acid for improved anti-tumor efficacy. Int J Pharm. 2017;531(1):153–166. doi:10.1016/j.ijpharm.2017.08.07628823888
   PubMed Web of Science ®Google Scholar
• Alakurtti S, Heiska T, Kiriazis A, Sacerdoti-Sierra N, Jaffe CL, Yli-Kauhaluoma J. Synthesis and anti-leishmanial activity of heterocyclic betulin derivatives. Bioorg Med Chem. 2010;18(4):1573–1582. doi:10.1016/j.bmc.2010.01.00320116263
   PubMedGoogle Scholar
• Domínguez-Carmona D, Escalante-Erosa F, García-Sosa K, et al. Antiprotozoal activity of betulinic acid derivatives. Phytomedicine. 2010;17(5):379–382. doi:10.1016/j.phymed.2009.08.00219748254
   PubMedGoogle Scholar
• Chowdhury S, Mukherjee T, Sengupta S, Chowdhury SR, Mukhopadhyay S, Majumder HK. Novel betulin derivatives as antileishmanial agents with mode of action targeting type IB DNA topoisomerase. Mol Pharmacol. 2015;80(4):694–703. doi:10.1124/mol.111.072785
   Google Scholar
• Chowdhury AR, Mandal S, Goswami A, et al. Dihydrobetulinic acid induces apoptosis in Leishmania donovani by targeting DNA topoisomerase I and II: implications in antileishmanial therapy. Mol Med. 2003;9(1–2):26–36.12765337
   PubMed Web of Science ®Google Scholar
• Pundir S, Badola A, Sharma D. Sustained release matrix technology and recent advance in matrix drug delivery system: a review. Int J Drug Res Technol. 2017;3(1):8.
   Google Scholar
• Koohi Moftakhari Esfahani M, Alavi SE, Shahbazian S, Ebrahimi Shahmabadi H. Drug delivery of cisplatin to breast cancer by polybutylcyanoacrylate nanoparticles. Adv Polymer Technol. 2018;37(3):674–678. doi:10.1002/adv.2018.37.issue-3
   Web of Science ®Google Scholar
• Doun SKB, Alavi SE, Esfahani MKM, Shahmabadi HE, Alavi F, Hamzei S. Efficacy of Cisplatin-loaded poly butyl cyanoacrylate nanoparticles on the ovarian cancer: an in vitro study. Tumor Biol. 2014;35(8):7491–7497. doi:10.1007/s13277-014-1996-8
   PubMedGoogle Scholar
• Shahabi J, Shahmabadi HE, Alavi SE, et al. Effect of gold nanoparticles on properties of nanoliposomal hydroxyurea: an in vitro study. Indian J Clin Biochem. 2014;29(3):315–320. doi:10.1007/s12291-013-0355-724966479
   PubMedGoogle Scholar
• Dehghani F, Hoseini MHM, Memarnejadian A, et al. Immunomodulatory activities of chitin microparticles on leishmania major-infected murine macrophages. Arch Med Res. 2011;42(7):572–576. doi:10.1016/j.arcmed.2011.11.00522154683
   PubMed Web of Science ®Google Scholar
• Malik A, Gupta M, Mani R, Gogoi H, Bhatnagar R. Trimethyl chitosan nanoparticles encapsulated protective antigen protects the mice against anthrax. Front Immunol. 2018;9:562. doi:10.3389/fimmu.2018.0056229616046
   PubMed Web of Science ®Google Scholar
• Malik A, Gupta M, Gupta V, Gogoi H, Bhatnagar R. Novel application of trimethyl chitosan as an adjuvant in vaccine delivery. Int J Nanomedicine. 2018;13:7959. doi:10.2147/IJN.S17762730538470
   PubMed Web of Science ®Google Scholar
• Salah R. Antileishmanial activities of chitin and chitosan prepared from shrimp shell waste. Int Conf Chem Mettalurgy Environ Eng. 2015;29:177–280.
   Google Scholar
• Jain V, Gupta A, Pawar VK, et al. Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles. Appl Biochem Biotechnol. 2014;174(4):1309–1330. doi:10.1007/s12010-014-1084-y25106894
   PubMed Web of Science ®Google Scholar
• Wang JJ, Zeng ZW, Xiao RZ, et al. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine. 2011;6:765. doi:10.2147/IJN.S2564621589644
   PubMed Web of Science ®Google Scholar
• MubarakAli D, LewisOscar F, Gopinath V, Alharbi NS, Alharbi SA, Thajuddin N. An inhibitory action of chitosan nanoparticles against pathogenic bacteria and fungi and their potential applications as biocompatible antioxidants. Microb Pathog. 2018;114:323–327. doi:10.1016/j.micpath.2017.11.04329229504
   PubMed Web of Science ®Google Scholar
• Singh PK, Pawar VK, Jaiswal AK, et al. Chitosan coated PluronicF127 micelles for effective delivery of amphotericin B in experimental visceral leishmaniasis. Int J Biol Macromol. 2017;105:1220–1231. doi:10.1016/j.ijbiomac.2017.07.16128780414
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang H, Wu Y. Dendrimer advances for the central nervous system delivery of therapeutics. ACS Chem Neurosci. 2013;5(1):2–13. doi:10.1021/cn400182z24274162
   PubMedGoogle Scholar
• Kalomiraki M, Thermos K, Chaniotakis NA. Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int J Nanomedicine. 2016;11:1–12. doi:10.2147/IJN.S9306926730187
   PubMed Web of Science ®Google Scholar
• Jain K, Verma AK, Mishra PR, Jain NK. Characterization and evaluation of amphotericin B loaded MDP conjugated poly (propylene imine) dendrimers. Nanomed. 2015;11(3):705–713. doi:10.1016/j.nano.2014.11.008
   PubMedGoogle Scholar
• Hypercube Incorporation. HyperChem (TM) Professional 8.0. Gainesville, FL: Hypercube, Inc.; 2007.
   Google Scholar
• Molecular Graphics Laboratory, Department of Molecular Biology, The Scripps Research Institute, MB-510550 N. Torrey Pines Rd. La Jolla, CA 92037-1000U.S.A. Available from: http://autodock.scripps.edu/faqs-help/tutorial/using-autodock-4-with-autodocktools.
   Google Scholar
• Zadeh Mehrizi T, Shafiee Ardestani M, Haji Molla Hoseini M, Khamesipour A, Mosaffa N, Ramezani A. Novel nano-sized chitosan amphotericin B formulation with considerable improvement against Leishmania major. Nanomedicine (Lond). 2018;13(24):3129–3147. doi:10.2217/nnm-2018-006330463469
   PubMedGoogle Scholar
• Zadeh Mehrizi T, Shafiee Ardestani M, Haji Molla Hoseini M, Khamesipour A, Mosaffa N, Ramezani A. Novel nanosized chitosan-betulinic acid against resistant Leishmania major and first clinical observation of such parasite in kidney. Sci Rep. 2018;8(1):11759. doi:10.1038/s41598-018-30103-730082741
   PubMedGoogle Scholar
• Zadeh Mehrizi T, Shafiee Ardestani M, Khamesipour A, et al. Reduction toxicity of amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major. J Mate Sci. 2018;29(8):125.
   Google Scholar
• Zadeh Mehrizi T, Shafiee Ardestani M, Khamesipour A, et al. Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major. Journal of Materials Science: Materials in Medicine 2018;29(8):125.
   Google Scholar
• Safari J, Azizi F, Sadeghi M. Chitosan nanoparticles as a green and renewable catalyst in the synthesis of 1, 4-dihydropyridine under solvent-free conditions. N J Chem. 2015;39(3):1905–1909. doi:10.1039/C4NJ01730G
   Google Scholar
• Jain A, Thakur K, Sharma G, Kush P, Jain UK. Fabrication, characterization and cytotoxicity studies of ionically cross-linked docetaxel loaded chitosan nanoparticles. Carbohydr Polym. 2016;137:65–74. doi:10.1016/j.carbpol.2015.10.01226686106
   PubMed Web of Science ®Google Scholar
• Mohammadi E, Amanlou M, Ebrahimi SES, et al. Cellular uptake, imaging and pathotoxicological studies of a novel Gd [III]–DO3A-butrol nano-formulation. RSC Adv. 2014;4(86):45984–45994. doi:10.1039/C4RA05596A
   Google Scholar
• Ghoreishi SM, Bitarafan-Rajabi A, Azar AD, Ardestani MS, Novel AA. 99mTc-radiolabeled anionic linear globular PEG-based dendrimer-chlorambucil: non-invasive method for in-vivo biodistribution. Drug Res. 2017;67(03):149–155. doi:10.1055/s-0042-118448
   Google Scholar
• Morakul B, Suksiriworapong J, Chomnawang MT, Langguth P, Junyaprasert VB. Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation–lyophilization–homogenization method. Eur J Pharm Biopharm. 2014;88(3):886–896. doi:10.1016/j.ejpb.2014.08.01325201298
   PubMed Web of Science ®Google Scholar
• Koch S, Kessler M, Mandel K, Dembski S, Heuze K, Hackenberg S. Polycarboxylate ethers: the key towards non-toxic TiO 2 nanoparticle stabilisation in physiological solutions. Colloids Surf B. 2016;143:7–14. doi:10.1016/j.colsurfb.2016.03.010
   PubMedGoogle Scholar
• Mahmoudvand H, Kheirandish F, Mirbadie SR, et al. The potential use of methotrexate in the treatment of cutaneous Leishmaniasis: in vitro assays against sensitive and meglumine antimoniate-resistant strains of Leishmania tropica. Iran J Parasitol. 2017;12(3):339.28979343
   PubMed Web of Science ®Google Scholar
• Abamor ES. Antileishmanial activities of caffeic acid phenethyl ester loaded PLGA nanoparticles against Leishmania infantum promastigotes and amastigotes. In Vitro. Asian Pacific J Trop Med. 2017;10(1):25–34. doi:10.1016/j.apjtm.2016.12.006
   PubMed Web of Science ®Google Scholar
• Vellozo NS, Pereira-Marques ST, Cabral-Piccin MP, et al. All-trans retinoic acid promotes an M1-to M2-phenotype shift and inhibits macrophage-mediated immunity to Leishmania major. Front Immunol. 2017;8:1560–1571. doi:10.3389/fimmu.2017.0156029204144
   PubMed Web of Science ®Google Scholar
• Marinho FA, Sangenito LS, Oliveira SS, et al. The potent cell permeable calpain inhibitor MDL28170 affects the interaction of Leishmania amazonensis with macrophages and shows anti-amastigote activity. Parasitol Int. 2017;66(5):579–583. doi:10.1016/j.parint.2017.06.01028663009
   PubMed Web of Science ®Google Scholar
• Davoudi N, Khamesipour A, Mahboudi F, McMaster WR. A dual drug sensitive L. major induces protection without lesion in C57BL/6 mice. PLoS Negl Trop Dis. 2014;8(5):e2785. doi:10.1371/journal.pntd.000278524873970
   PubMed Web of Science ®Google Scholar
• Kheirandish F, Mahmoudvand H, Khamesipour A, et al. The therapeutic effects of olive leaf extract on Leishmania major infection in BALB/c mice. Marmara Pharm J. 2017;21(4):837–842. doi:10.12991/mpj.2017.6
   Google Scholar
• Hoseini MHM, Moradi M, Alimohammadian MH, Shahgoli VK, Darabi H, Rostami A. Immunotherapeutic effects of chitin in comparison with chitosan against Leishmania major infection. Parasitol Int. 2016;65(2):99–104. doi:10.1016/j.parint.2015.10.00726518128
   PubMedGoogle Scholar
• Ghotloo S, Mollahoseini MH, Najafi A, Yeganeh F. Comparison of parasite burden using real-time polymerase chain reaction assay and limiting dilution assay in leishmania major infected mouse. Iran J Parasitol. 2015;10(4):571.26811723
   PubMedGoogle Scholar
• Hajjaran H, Kazemi‐Rad E, Mohebali M, et al. Expression analysis of activated protein kinase C gene (LACK 1) in antimony sensitive and resistant Leishmania tropica clinical isolates using real‐time RT‐PCR. Int J Dermatol. 2016;55(9):1020–1026. doi:10.1111/ijd.1332127336481
   PubMedGoogle Scholar
• Zadeh Mehrizi T, Mosaffa N, Haji MollaHoseini M, Shafiee Ardestani M, Khamesipour A, Ramezani A. In vivo therapeutic effects of four synthesized antileishmanial nanodrugs in the treatment of Leishmaniasis. Arch Clin Infect Dis. 2018;13(5):e80314.
   Google Scholar
• Huynh CT, Lee DS. Controlled release. Encycl Polym Nanomate. 2015;4(Springer):439–449.
   Google Scholar
• Tamizharasi S, Dubey A, Rathi V, Rathi J. Development and characterization of niosomal drug delivery of gliclazide. J Young Pharm. 2009;1(3):205. doi:10.4103/0975-1483.57065
   Google Scholar
• Irby D, Du C, Li F. Lipid–drug conjugate for enhancing drug delivery. Mol Pharm. 2017;14(5):1325–1338. doi:10.1021/acs.molpharmaceut.6b0102728080053
   PubMed Web of Science ®Google Scholar
• Barzegar-Jalali M, Adibkia K, Valizadeh H, et al. Kinetic analysis of drug release from nanoparticles. J Pharm Pharm Sci. 2008;11(1):167–177.18471378
   PubMed Web of Science ®Google Scholar
• Ribeiro TG, Fumagalli MAC, Valadares DG, et al.Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system. Int J Nanomedicine, 2014;9:877–890.
   Google Scholar
• Jain K, Verma AK, Mishra PR, Jain NK. Surface-engineered dendrimeric nanoconjugates for macrophage-targeted delivery of amphotericin B: formulation development and in vitro and in vivo evaluation. Antimicrob Agents Chemother. 2015;59(5):2479–2487. doi:10.1128/AAC.04213-1425645852
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, Boyd BJ, Porter CJ. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine. 2011;6(6):1063–1084. doi:10.2217/nnm.11.6721955077
   PubMed Web of Science ®Google Scholar
• Gupta PK, Jaiswal AK, Asthana S, et al. Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis. Pharm Res. 2015;32(5):1727–1740. doi:10.1007/s11095-014-1571-425425053
   PubMed Web of Science ®Google Scholar
• Dash M, Chiellini F, Ottenbrite R, Chiellini E. Chitosan—A versatile semi-synthetic polymer in biomedical applications. Prog Polym Sci. 2011;36(8):981–1014. doi:10.1016/j.progpolymsci.2011.02.001
   Web of Science ®Google Scholar
• Sousa MC, Varandas R, Santos RC, Santos-Rosa M, Alves V, Salvador JA. Antileishmanial activity of semisynthetic lupane triterpenoids betulin and betulinic acid derivatives: synergistic effects with miltefosine. PLoS One. 2014;9(3):e89939. doi:10.1371/journal.pone.008993924643019
   PubMedGoogle Scholar
• Daftarian PM, Stone GW, Kovalski L, et al. A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis. J Infect Dis. 2013;208(11):1914–1922. doi:10.1093/infdis/jit37823901083
   PubMed Web of Science ®Google Scholar
• Asthana S, Jaiswal AK, Gupta PK, Pawar VK, Dube A, Chourasia MK. Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules. Antimicrob Agents Chemother. 2013;57(4):1714–1722. doi:10.1128/AAC.01984-1223357762
   PubMed Web of Science ®Google Scholar
• Shahnaz G, Edagwa BJ, McMillan J, et al. Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis. Nanomedicine. 2017;12(2):99–115. doi:10.2217/nnm-2016-032527879160
   PubMedGoogle Scholar